Skip to main content
main-content

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

Editor's pick

11-06-2019 | Non-small cell lung cancer | ASCO 2019 | News

RELAY: Ramucirumab–erlotinib a potential first-line option for EGFR-mutated NSCLC

Combining erlotinib with ramucirumab significantly improves the progression-free survival of untreated patients with advanced EGFR mutation-positive non-small-cell lung cancer, suggest phase III results presented at the 2019 ASCO Annual Meeting in Chicago, Illinois, USA.

17-06-2019 | Prostate cancer | Video | Article

MRI-targeted biopsy for prostate cancer diagnosis

Veeru Kasivisvanathan explains the background and clinical implications of the PRECISION trial, which tested whether using multiparametric MRI with a targeted biopsy was noninferior to standard transrectal ultrasonography–guided biopsy in the detection of clinically significant prostate cancer.

10-04-2019 | Urothelial cancer | Video | Article

Adjuvant chemotherapy for upper tract urothelial cancer

Alison Birtle discusses the rationale for adjuvant chemotherapy for upper tract urothelial cancer (UTUC), the POUT trial and its practice-changing implications for treatment of UTUC.

ASCO 2019 coverage

View all of our coverage of the 2019 ASCO Annual Meeting in Chicago (May 31–June 4).

Specialty

Latest from across the site

19-06-2019 | Non-small cell lung cancer | ASCO 2019 | News

No survival boost for advanced NSCLC with metformin

Metformin does not improve progression-free survival for patients without diabetes who require chemoradiotherapy for stage IIIA or IIIB non-small-cell lung cancer, suggests research presented at the 2019 ASCO Annual Meeting in Chicago, Illinois, USA.

19-06-2019 | Radiotherapy | ASCO 2019 | Article

Researcher comment: Fewer AEs with proton versus photon radiotherapy

Brian Baumann presents their comparative analysis of the adverse event profiles of proton and photon radiotherapy in nonmetastatic patients receiving chemoradiotherapy with curative intent for various solid tumors, including lung cancer (5:28).

18-06-2019 | Renal cell carcinoma | ASCO 2019 | News

Sarcomatoid RCC patients benefit from immune checkpoint inhibitor therapy

Subgroup analysis of the IMmotion151 trial suggests improved survival with first-line atezolizumab plus bevacizumab versus sunitinib for locally advanced or metastatic renal cell carcinoma patients with sarcomatoid differentiation.

18-06-2019 | Non-small cell lung cancer | ASCO 2019 | News

Broadening clinical trial inclusion criteria doubles number of eligible NSCLC patients

Using expanded criteria for clinical trial inclusion could lead to nearly twice as many patients with advanced non-small-cell lung cancer being eligible for participation compared with traditional criteria, participants at the 2019 ASCO Annual Meeting in Chicago, Illinois, USA, heard.

17-06-2019 | Urothelial cancer | ASCO 2019 | News

Bevacizumab adds no value to chemotherapy for metastatic urothelial cancer

Adding bevacizumab to gemcitabine plus cisplatin chemotherapy does not improve overall survival when used as first-line therapy for metastatic urothelial carcinoma, show results of the phase III CALGB 90601 study.

17-06-2019 | Prostate cancer | Video | Article

MRI-targeted biopsy for prostate cancer diagnosis

Veeru Kasivisvanathan explains the background and clinical implications of the PRECISION trial, which tested whether using multiparametric MRI with a targeted biopsy was noninferior to standard transrectal ultrasonography–guided biopsy in the detection of clinically significant prostate cancer.

Meet the Editorial Board


Our international Editorial Board members Dr Fiona Blackhall (Christie Hospital, Manchester, UK) and Dr Axel Merseburger (University Hospital Schleswig-Holstein, Germany) work closely with the editorial team to highlight gaps in coverage and select topics to feature on this digital platform.

Why register? Medicine Matters oncology is a free resource providing the latest news and clinical guidance

Register today and receive updates directly to your inbox!
Medicine Matters oncology has been specifically developed for the time-limited healthcare professional who is looking for a single resource providing credible information on current practice and the latest advances in oncology.
Already registered? Log in now to unlock your access.

Latest from us on Twitter

Updates from oncology organizations

New Content Item Meet our Advisory Board

Image Credits